The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).
 
Hiroaki Akamatsu
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - MSD
Other Relationship - Abbvie
 
Hibiki Udagawa
Honoraria - Abbvie; Amco; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim
Research Funding - Abbvie; Amgen; Daiichi Sankyo; MSD
 
Kentaro Tanaka
Honoraria - Chugai Pharma
Research Funding - Boehringer Ingelheim; Chugai/Roche; Ono Pharmaceutical
 
Masayuki Takeda
No Relationships to Disclose
 
Shintaro Kanda
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical
Research Funding - Abbvie; AstraZeneca; Ono Pharmaceutical
 
Keisuke Kirita
Honoraria - AMCo; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Kyowa Hakko Kirin; Meiji Seika Kaisha; MSD Oncology; Novartis; Olympus; Pfizer
Research Funding - Chugai Pharma; MSD Oncology; Pfizer
 
Shunsuke Teraoka
No Relationships to Disclose
 
Kazuhiko Nakagawa
Honoraria - Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb; CareNet; Chugai Pharma; Clinical Trial Co; Daiichi Sankyo; Hisamitsu Pharmaceutical; Kyorin; Lilly; Medical Review Co., Ltd.; Medicus Shuppan Publishers; Merck Sharp & Dohme; NANZANDO Co.,Ltd.; Nichi-iko; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Reno Medical; SymBio Pharmaceuticals; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; YODOSHA; Yomiuri Telecasting Corporation
Speakers' Bureau - Astellas Pharma; Ono Pharmaceutical; Takeda
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); Gritstone Bio (Inst); ICON Clinical Research (Inst); inVentiv Health (Inst); IQvia (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Linical (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Quintiles Inc. (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yutaka Fujiwara
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; MSD; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical
Research Funding - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Lilly; Merck Serono; MSD; Novartis
 
Ikuko Yasuda
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Sumiko Okubo
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Masayuki Shintani
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Rachel S Leibman
Employment - Abbvie/Stemcentrx
Stock and Other Ownership Interests - Abbvie/Stemcentrx
 
Charity D. Scripture
Employment - Abbvie/Stemcentrx
Stock and Other Ownership Interests - Abbvie/Stemcentrx
 
Tomohide Tamura
Honoraria - Boehringer Ingelheim; Chugai Pharma; CMIC; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)